AlphaFold2-based structure prediction and target study of PD-L1 protein

Zhuoya Yang

doi:10.54254/2753-8818/3/20220152

Article Information

Received: 24 April 2023

Published: 28 April 2023

DOI: https://doi.org/10.54254/2753-8818/3/20220152

Article Type: Research Article

Cite this article

Yang,Z. (2023). AlphaFold2-based structure prediction and target study of PD-L1 protein. Theoretical and Natural Science,3,1-10.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.3

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., ... & Hirsch, F. R. (2021). PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 18(6), 345-362

[2]Alsaab, H. O. , †, Sau, S. , Alzhrani, R. , & Tatiparti, K. . PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.

[3]Munn, D. H. , & Bronte, V. . (2016). Immune suppressive mechanisms in the tumor microenvironment. Current Opinion in Immunology, 39, 1-6.

[4]Lee, H. T., Lee, S. H., & Heo, Y. S. (2019). Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules, 24(6), 1190.R.T.

[5]Tan, S., Chen, D., Liu, K., He, M., Song, H., Shi, Y., ... & Gao, G. F. (2016). Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein & cell, 7(12), 866-877.

[6]Jumper,J., Evans, R., Pritzel, A. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583-589(2021).

[7]Thornton, J. M., Laskowski, R. A., & Borkakoti, N. (2021). AlphaFold heralds a data-driven revolution in biology and medicine. Nature Medicine, 27(10), 1666-1669.

[8]Consortium, U. P. . (2020). Uniprot: the universal protein knowledgebase in 2021. Nucleic Acids Research(D1), D1.

[9]Tunyasuvunakool, K., Adler, J., Wu, Z., Green, T., Zielinski, M., Žídek, A., ... & Hassabis, D. (2021). Highly accurate protein structure prediction for the human proteome. Nature, 596(7873), 590-596.10 Mullard, A. (2021).

[10]What does AlphaFold mean for drug discovery?. Nature reviews. Drug discovery.

[11]Ormo, M., Cubitt, A.B., Kallio, K., Gross, L.A., Tsien, R.Y., Remington, S.J. (1996) Crystal structure of the Aequorea victoria green fluorescent protein Science 273: 1392-1395 doi: 10.1126/science.273.5280.1392

[12]Perry, E. , Mills, J. J. , Zhao, B. , Wang, F. , Sun, Q. , & Christov, P. P. , et al. (2019). Fragment-based screening of programmed death ligand 1 (pd-l1). Bioorganic & Medicinal Chemistry Letters.

[13]Lee, H. T. , Lee, J. Y. , Lim, H. , Lee, S. H. , Moon, Y. J. , & Pyo, H. J. , et al. (2017). Molecular mechanism of pd-1/pd-l1 blockade via anti-pd-l1 antibodies atezolizumab and durvalumab. Rep, 7(1), 5532.

[14]Delano, W. L. . (2002). PyMOL: An Open-Source Molecular Graphics Tool.

[15]Sebastian, S. , Sven, S. , Joachim, H. V. , Adasme, M. F. , & Michael, S. . (2015). Plip: fully automated protein–ligand interaction profiler. Nucleic Acids Research(W1), W443.